** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020
** Stock marks biggest intraday pct gain since October 5, 2023
** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.
** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease
** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg
** Last up 50%, DXB more than doubles YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。